AdaptHealth guidance cut investigation

AdaptHealth Corp. (NASDAQ: AHCO) reported second quarter 2026 revenue of $740.3 million, well below the approximately $847 million expected, and a GAAP loss of $0.99 per share, driven in part by a $144.2 million goodwill impairment charge. Adjusted EBITDA came in at $132 million versus roughly $160 million expected. The company also substantially reduced its full-year 2026 guidance, resetting revenue to approximately $2.85 billion to $2.89 billion and adjusted EBITDA to $490 million to $520 million, down from the $680 million to $730 million range provided on May 5, 2026. Management attributed the reset to the Diabetes Health divestiture, a capitated contract, manufacturer pricing, and other portfolio actions. Following the announcement, shares fell as much as 26%. Levi & Korsinsky, LLP has commenced an investigation into potential violations of federal securities laws, focusing on whether AdaptHealth made materially false or misleading statements regarding its 2026 guidance and the normalization of elevated labor costs. The investigation is ongoing, and investors who suffered losses are being solicited for potential recovery.